contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  createdAt
  changedAt
  isPremium
  authors {
    __typename
    name
    pageUrl
    id
  }
  companies {
    name
    pageUrl
    id
  }
  tags {
    name
    id
  }
  ... on Video {
    liveTime
    videoUrl
    videoEmbedUrl(location: "inderes")
  }
  ... on Webcast {
    liveTime
    videoUrl
    videoEmbedUrl(location: "inderes")
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
      researchContentUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


constitutive-meeting-of-biohit-oyjs-board-of-directors-8

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

changedAt

Biohit operates in the medical technology sector. The company develops and manufactures laboratory equipment, consumables and diagnostic analysis systems adapted for research, healthcare and industrial laboratories. In addition to its main business, it offers technical support, maintenance and training services within the aforementioned field of work. The largest operations are conducted in the Nordic market. The company has its headquarters in Helsinki.

And then the final, most important question: At what price?

The notice of the Annual General Meeting seeks authorization for the Board to issue a fairly large number of shares. I wonder if there is already something in the works, or what this might be about? There haven’t been authorizations like that in previous years.

Here are Antti’s comments on Biohit’s latest good news  Biohit announced on Tuesday a new peer-reviewed study, the results of which supported the company’s value proposition regarding the benefit of the GastroPanel test in gastric cancer risk stratification and shortening treatment queues. The research results provide the company with important scientific evidence to support sales and marketing, which is crucial particularly in new market areas and public healthcare projects. The study is based on a project conducted in Chile, which has already led to the implementation of GastroPanel as part of a national cancer prevention strategy.                   Inderes – 22 Apr 26              Tutkimus: Biohitin GastroPanel lyhensi hoitojonoja - Inderes    Endoskopiajonot lyhenivät 87 prosentilla.

Nasdaq Company News              Vertaisarvioitu tutkimus vahvistaa GastroPanel®-testin arvon...                               Peer-reviewed study confirms the value of the GastroPanel® test in reducing endoscopy queues A new peer-reviewed publication in the prestigious Helicobacter journal (2026) confirms the clinical utility of the GastroPanel® test as a non-invasive triage tool for gastric cancer risk stratification. GastroPanel® combines a biomarker-based test with risk algorithms, enabling safe prioritization of patients for endoscopy and reducing unnecessary procedures. In a practical implementation in Chile (Molina), the method led to an 87% reduction in endoscopy queues and ensured rapid access to endoscopy for high- and medium-risk patients. “This is a very significant milestone for Biohit and healthcare systems worldwide,” says Jussi Hahtela, CEO of Biohit Oyj. “We now have peer-reviewed evidence that endoscopy queues can be reduced by up to 87% without compromising patient safety. The scarcity of healthcare resources is a global challenge, and GastroPanel® offers a practical, evidence-based solution for more efficient resource allocation and improving early detection of gastric cancer.” The results strengthen the position of the GastroPanel® test as a scalable and evidence-based solution for promoting early detection of gastric cancer and for more efficient allocation of healthcare resources worldwide.

Warning: this post is pure speculation and irresponsible doom-mongering. I don’t actually have any idea what the most likely outcome will be. It could go well or very badly​ I can’t say anything more specific regarding the need for cash or possible share issues, but I personally consider the Hefei and China business operations to be the greatest risk. There are €7.5 million in receivables from Hefei, against which there is a pledge of 1.5 million B-shares (value approx. €4.5 million). The matter is further complicated by the fact that Hefei is Biohit’s second-largest owner (over 20% of shares and votes) and, additionally, China is Biohit’s most important market (Asia accounted for nearly half of the revenue in 2025), the distribution of which is handled by Hefei. One can then wonder what happens if Hefei, for one reason or another, gets into financial difficulties and is at risk of total collapse. Or what if Hefei is nationalized in the name of China’s public health​ The receivables would go unpaid, the pledge could be liquidated, but at what price if the distributor for the most important market collapses? In that case, would Hefei also sell the rest of its holdings at a fire-sale price to the other major owner? Quite many other things could also go wrong related to this. The problem and risk simply culminate in the fact that, from the outside, a private investor has no way of assessing the probabilities of these options.

This really good clarification by @JP199 to my own previous ramblings kept playing on my mind disturbingly. I have hyped up the company’s great openings (UK, India, South Korea, Chile) and their immense potential here. In my opinion, this “ketchup bottle effect” is still real. However, I now have one tiny reservation about it, at least at the current share price. According to Inderes, the company is delivering strong results. “Biohit’s operating profit (EBIT) in H2 was EUR 1.7 million, which grew strongly from the comparison period and exceeded our forecast (EUR 1.3 million). The operating margin was an excellent 21% in H2 and 19% for the full year.” Except that the money isn’t landing in the company’s account. “Operational cash flow for the full year remained EUR 0.7 million negative (H2: +0.2 MEUR).” Quotes here: Biohit H2'25: Vahva tulos – kasvunäkymät aiempaa maltillisemmat - Inderes According to the Stockanalysis.com website, FCF was 0.2M in H2/2025 and solidly in the red at -1.5M in the first half of the year. So, the free cash flow for 2025 was -1.3 million. The thing that hit me hardest today is the following: The company had cash (Cash & Equivalents) of 3.5M on Dec 31, 2025. The amount of cash has remained pretty much the same compared to H2/2024 (3.8M) and H1/2025 (3.9M). A slight decrease, which I’m not worried about. But. Short Term Investments have collapsed to zero during that time.  H2/2024 3M H1/2025 1.3M and H2/2025 0  So the entire cash-equivalent position (Cash & Short Term Investments) has nearly halved (-47.8%) since H2/2024  H2/2024 6.7M H1/2025 5.2M H2/2025 3.5M  The company only has actual cash left. Antti also noted that:  So we have a company that makes a strong, growing profit on paper. At the same time, it has burned through its cash-equivalent assets without (at least yet) having to touch the hard cash itself. Now only that 3.5M in cash remains. How far will it last when even the analyst warns that no money is currently coming into the company, and that those large (and exceptional) licensing revenues from China were practically it? How big of an operation do you believe can be launched in the UK, India, South Korea, and Chile with 3.5 million? My guess (which I hope with all my heart proves to be wrong) is that more money will still be needed. Possibly quite soon. How large a (directed) share issue or, at worst, even a convertible bond (VVK) arrangement would you expect? At what stage? And at what price?

Phew, wow, and oh my goodness. Huge and most humble thanks to both @JP199 and @Antti_Siltanen !! I admit I was completely in the dark that the situation regarding those receivables is this bad. This is starting to remind me of the TEM1V case one-to-one (1:1). As I have written, I believe in the product and its value-add for customers like a rock. I no longer believe so much in the company itself, or especially its leading insiders. I am still strongly of the opinion that Biohit’s (BIOBV) international openings and approvals last year (UK, South Korea, India, Chile) especially build huge potential that is materializing right now. This is mentally tough. I felt forced to reduce my holding by 40%. Ha, just after I had loaded back up to the max last Friday =). There are (for me personally) too high risks here that the share price level will be driven down even lower before what I believe is a completely possible VMBO (buyout) offer is made. If I were even half sure that the offer I predicted with my tinfoil hat on could come, for example, at the current level or even after the price rose a bit from here, I would probably stay sitting on my hands and my whole position. Now, however, it’s slowly starting to seem like 80s-style Wall Street is being cautiously tested in our small-town stock exchange. It feels like there are already a few of these cases ongoing or starting. I wonder if some pantyhose-selling consultancy firm has found a “completely new and original” angle to advise their clients (and themselves at the same time) on how to make some faster BIG money? Yep, I’m clicking BIOBV off my active price monitoring and will stop grinding out conspiracy theories (in this thread) at the same time. Godspeed to everyone with this, great success! Kiitos. Edit(s).  The word BIG added. Apology removed. I do stand by these thoughts, however. The thanks at the end still stands.

Biohit

Biohit Oyj, Other information disclosed according to the rules of the Exchange, June 5, 2026 at 6:00 pm local time (EEST)Biohit Oyj’s Board of Directors has in its meeting on June 5, 2026 elected...

Biohit Oyj, Other information disclosed according to the rules of the Exchange, June 5, 2026 at 6:00 pm local time (EEST)Biohit Oyj’s Board of Directors has in its meeting on June 5, 2026 elected Professor Kari Syrjänen as the Chairman of the Board of Directors.Syrjänen’s strong scientific expertise supports the work of the Board of Directors and the development of the company.Additional information:&nbsp; CEO Jussi Hahtela, Biohit Oyjtel. +358 9&nbsp;773 861investor.relations@biohit.fi www.biohithealthcare.com&nbsp;Biohit in briefBiohit Oyj is a globally operating Finnish biotechnology company. Biohit mission is “Innovating for Health” – we produce innovative products and services to promote research and early diagnosis. Biohit is headquartered in Helsinki, Finland, and has subsidiaries in Italy and the UK. Biohit Series B share (BIOBV) is quoted on Nasdaq Helsinki in the Small cap/Healthcare group.&nbsp;<a href="https://www.globenewswire.com/Tracker?data=ciyb_iZ945H2z3sK3a9i7Zs03Nkj9jr5Brw7kC1tsoUye5PVgko06PC57Z9BVVT2pXUgp6sn-tswLd2MUgQOQc8UNXD2BkNm3L02XzRJ7XfJCPaPUqGS1mpI0NZinK5T">www.biohithealthcare.com</a>

Constitutive meeting of Biohit Oyj’s Board of Directors

Constitutive meeting of Biohit Oyj’s Board of Directors